Tovecimig (ctx-009) meets primary endpoint in the ongoing randomized phase 2/3 study in patients with biliary tract cancer

Tovecimig (a dll4 x vegf-a bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (orr), including one complete response, compared to 5.3% orr for paclitaxel alone, in patients with biliary tract cancer (btc) treated in the second-line setting. the difference in orr between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review.
CMPX Ratings Summary
CMPX Quant Ranking